Jeff George

About Jeff George

Global healthcare investor, board director and chairman, and former global CEO of Sandoz and Alcon, two $10 billion revenue subsidiaries of Novartis Group (NYSE: NVS), where Jeff served on the Executive Committee between 2008 and 2016. Jeff is currently the Managing Partner of Maytal Capital, a healthcare-focused venture capital and private equity investment and advisory firm he founded in 2017 which has made over 45 direct investments. He also serves on a range of public, private, and non-profit boards.Jeff currently serves as Chairman of LENZ Therapeutics (NASDAQ: LENZ), an ophthalmic biotech whose lead program in presbyopia has completed Phase 3 trials, and since 2019 as a Board Director at Amneal Pharmaceuticals (NASDAQ: AMRX), a high-growth leader in specialty and complex generic pharmaceuticals with over $3 billion in revenues. He previously served on the boards of 908 Devices (NASDAQ: MASS), a pioneer in chemical and bioprocessing diagnostics, and Dorian Therapeutics, an early-stage biotech spun out of Stanford University, as well as on several non-profit boards including the North Texas Food Bank (20••••25) and Education Opens Doors (20••••23, as Chairman). Between 2022 and 2025, he also served as Chairman of CNS-focused biopharma company Lykos Therapeutics.Between 2008 and 2016, Jeff served on the Executive Committee of Switzerland-based Novartis Group AG, one of the world\'s largest pharmaceutical companies, first as CEO & Division Head of now publicly-listed Sandoz, Novartis’s then nearly $10 billion generic pharmaceuticals and biosimilars subsidiary headquartered in Munich, Germany which doubled in value during his tenure, and then as CEO & Division Head of Texas-based Alcon, Novartis’s then ~$10 billion eye care subsidiary which since 2019 has been publicly listed (NYSE: ALC). In both of these roles at Novartis, Jeff was responsible for leading over associates globally across more than 160 countries and had leadership and management responsibility for all functions, regions, and franchises. Prior to this he held leadership roles at Novartis Pharmaceuticals, Novartis Vaccines, Gap Inc, and McKinsey & Co.Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was a John W. Watzek Fellow. He received his B.A. in international relations from Carleton College, where he graduated magna cum laude and Phi Beta Kappa.

Experience

1. Board Director

   Amneal Pharmaceuticals

   Dec 2019 — Present · Bridgewater, NJ, US

   Amneal Pharmaceuticals (NASDAQ: AMRX) is a leading specialty and generic pharmaceutical company which in 2025 had revenues of $3.0 billion and EBITDA of $688 million, up from $1.6 billion and $339m in 2019 (+89% and +103% vs. 2019, respectively). Independent Board Director and Member of Audit, Compensation, and Conflict (independent director) committees since Feb. Between 2020 and 2022, served as Chairman of the Technology & Operational Compliance committee, which had board oversight over the R&D, Manufacturing, and Quality Assurance functions until its scope was folded back into the full

Education

• Carleton College

  Bachelor of Arts (B.A.), International Relations, Phi Beta Kappa, magna cum laude

  1994 — 1996

• Harvard Business School

  Master of Business Administration (MBA)

  1999 — 2001

• Breck School

  High School; Minneapolis, MN

• Johns Hopkins School of Advanced International Studies (SAIS)

  Master's degree, Int'l Economics & Emerging Markets Political Economy concentrations; John W. Watzek Fellow; Top 10%

  1998 — 1999